Hematogenous candidiasis is a life-threatening infection that has shown a dramatic increase in incidence over the last decades. In a 1984 nationwide survey of medical and surgical patients, Candida species were the eighth most common cause of nosocomial bloodstream infection [1] . In a similar survey conducted between October 1986 and December 1990, Candida species became the fourth leading cause of nosocomial bloodstream infection [2] . Data from NNIS hospitals also show that the incidence of primary bloodstream infections due to Candida increased by 487% in large teaching hospitals from 1980 to 1989 and by 219% increase in small (<200 beds) hospitals [3, 4] .
Hematogenous candidiasis adds substantially to the morbidity and mortality of critically ill patients with an attributable mortality of 38% and a prolongation of hospital stay by as much as 30 days [5] . In patients with cancer, the overall mortality is even higher.
Because of the high morbidity and mortality, it would be useful to identify prognostic features so that therapeutic strategies could be tailored accordingly. However, few studies have focused on the predictors of outcome in patients with candidemia. Even fewer data are present in patients with cancer. In this review, we will discuss the current literature on the prognostic factors in candidemic patients, with particular emphasis on patients with cancer.
A MEDLINE search was conducted for all study reports published from 1974 to 1999 on candidemia and prognostic factors including predictors of mortality. The review yielded a total of 73 articles. Ten articles provided sufficient data and were evaluated in detail (Table 1) .
Seven of these studies were retrospective in origin [6-9, 11, 12, 14] . The sample size ranged from 54 to 476 patients. Five studies were conducted in a heterogenous population of patients with the diagnosis of nosocomial candidemia [6] [7] [8] [9] [10] . Overall, the mortality rate was reported to be 33%-75%. Univariate analyses identified the following prognostic variables: severity of underlying disease, performance status, neutropenia, Candida species, source of candidemia and the extent of visceral involvement. In multivariate analyses, however, only host factors and extent of infection (rather than infecting Candida species) were predictive of mortality. These host factors included: severity of underlying disease, performance status (APACHE II or III, Simplified Physiologic Score, Karnofsky score, others), persistent neutropenia, and visceral dissemination. However, none of these five studies evaluated prognostic factors in cancer patients.
Our group conducted a study on the prognostic factors for outcome in 476 consecutive cancer patients with candidemia at M.D. Anderson Cancer Center during a five-year period. Overall mortality was 52% [14] . Mortality was greater among neutropenic patients (63% vs. 43%). Underlying disease (leukemia > lymphoma/ myeloma > solid tumor), shock at the time of positive blood culture, severity of illness (as judged by Simplified Acute Physiology Score and APACHE III), visceral dissemination, and becoming or remaining neutropenic were strongly associated with poor outcome, three months after the first positive blood culture (P ^ 0.001). Treatment with any antifungal agent was associated with a higher success rate (62% vs. 42%, P -0.004). The choice of amphotericin B or fluconazole as initial therapy had no impact on outcome. In multivariate analysis, increasing severity of illness (P < 0.0001), visceral dissemination (P < 0.0001), remaining or becoming neutropenic (P < 0.0001), were poor prognostic indicators. In addition, treatment with an antifungal agent was beneficial in non-neutropenic patients. Recent use of corticosteroids was also associated with a worse outcome in the non-neutropenic group of patients. Two additional studies evaluated the prognostic factors of candidemia in cancer patients with multivariate analysis (with 5% confidence intervals) (Table 2) [13, 15] . These studies identified prognostic factors comparable to those reported by us, including: Performance status, age, persistent neutropenia, stage of cancer, recent chemotherapy, and the presence of shock.
Controversy remains regarding the role of central venous lines as factors predicting outcome in candidemia. Nguyen et al. [10] reported a worse prognosis in patients whose catheters were retained (no 95% confidence intervals given), whereas our study [14] and that of Carroll et al. [9] and Nucci et al. [13] failed to show a major role for retention of central venous catheters in the outcome of candidemia.
In our study, we examined the impact of catheter management on outcome in 416 cancer patients with candidemia who had an indwelling catheter in place at the time of candidal infection. Catheter exchange within zero, two, or four days of the first positive blood culture had no significant effect on the outcome [14] . A second analysis performed in a subset of 363 patients who had a central venous catheter in place and received antifungal therapy revealed that catheter exchange was associated with improved outcome (80% vs. 54%, P < 0.001). However, the no-exchange group of patients had higher APACHE III scores and were more likely to be neutropenic. By multivariate analysis, catheter retention was not found to significantly affect outcome.
In a recent study in non-cancer patients, Rex et al. showed that replacement of all vascular catheters shortened the duration of candidemia from 5.6 days to 2.6 days [16] . This finding suggests that catheters may play a role in perpetuating infection in non-neutropenic patients. On the other hand, the primary source of candidemia is usually the gastrointestinal tract in neutropenic Nucci,
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• Age patients, not the intravenous catheter, and other factors such as severity of disease, visceral dissemination and neutrophil recovery appear to have more impact on the outcome of candidemia. The role of the in vitro susceptibilty pattern of the infecting Candida species as a predictor of outcome in patients with candidemia is not clear. The correlation between antifungal susceptibility testing and in vivo response was shown in a murine model of candidiasis [17] . Antifungal therapy significantly prolonged survival and reduced fungal burden in animals infected with Candida species susceptible to the agent tested, whereas in vitro resistance predicted the lack of/'/? vivo activity of that particular drug. In their clinical study, Rex et al. performed in vitro susceptibility testing on 232 bloodstream isolates of Candida collected during a clinical trial comparing fluconazole with amphotericin B in non-neutropenic patients [18] . Elevated MICs did not predict treatment failure on fluconazole. In the case of amphotericin B, the MIC range was too narrow to permit identification of resistant isolates. In a multicenter observational study, 105 Candida isolates obtained from the bloodstream of patients treated with amphotericin B were tested for amphotericin B [19] . No direct correlation was shown between amphotericin B MICs of specific organisms and outcome of infection; but treatment failure was observed among 100% of isolates with MICŝ 1 ug/ml compared with only 28% of those with MICs < 1 ug/ml. In this study, minimal lethal concentration determined at 48 hours was the strongest predictor for microbiological failure. To date, no single clinical study has evaluated the in vitro-in vivo correlation among cancer patients with candidemia.
In conclusion, the most important prognostic factors for candidemia in cancer patients include: Older age, poor performance status, presence and persistence of neutropenia, and extensive organ involvement with candidiasis. Although central venous catheter retention appears to play a minimal role in the outcome, a multicenter prospective study with the primary objective of intravenous catheter management should be designed to provide a definite answer to this question.
